Mankind Pharma Ups Investment In Subsidiary As Q4 FY26 Profit Climbs

Nikunj Parikh - Mumbai Bureau May 19, 2026 4,000 Views

Mankind Pharma has reported a strong set of Q4 FY26 and full-year numbers, backed by robust domestic formulations growth, improved profitability and disciplined balance-sheet management. The board has also cleared an additional investment of up to ₹500 crore in wholly owned arm Mankind Medicare, signalling continued focus on capacity and expansion.

Mankind Pharma Limited reported healthy revenue growth and resilient margins in the March quarter, aided by its core pharmaceuticals and healthcare portfolio. The company also continued to streamline its capital structure, realign security cover for debentures and reinforce its subsidiary network.

March Quarter And FY26 Performance

For Q4 FY26, Mankind Pharma’s consolidated revenue from operations stood at ₹34,42.93 crore, while profit from continuing operations came in at ₹5,59.42 crore. For FY26, consolidated revenue from operations reached ₹1,42,77.64 crore and profit from continuing operations totalled ₹19,38.10 crore, with net profit margin at about 13 percent on a trailing twelve‑month basis. The group’s EBITDA for FY26 stood at ₹3,499.35 crore, implying a net debt to EBITDA of 1.14x and net debt to equity of 0.25x, underlining a comfortable leverage profile.

Strategic Investment In Mankind Medicare

The board has approved additional investment of up to ₹500 crore in Mankind Medicare Private Limited, a wholly owned subsidiary, in one or more tranches. This follows continued deployment of capital into subsidiaries across domestic and international markets to support branded generics, speciality therapies and allied healthcare ventures. The move is aimed at strengthening manufacturing, product pipeline and future growth platforms within the group.

Governance, Debenture Cover And Tax Matters

The board has approved realignment of security cover for existing listed non‑convertible debentures post redemption of ₹1,250 crore of NCDs on April 16, 2026, with cover to shift from subsidiary securities to tangible and intangible assets of the company. It also reappointed a whole‑time director and cost auditors, and took note of the resignation of the Global CIO effective May 31, 2026. The company and certain group entities continue to contest income‑tax demands arising from search‑related proceedings, but management expects no material impact on financials.

Key highlights

Strong FY26 consolidated revenue of ₹1,42,77.64 crore and profit of ₹19,38.10 crore from continuing operations
Q4 FY26 consolidated revenue of ₹34,42.93 crore and profit of ₹5,59.42 crore from continuing operations
EBITDA of ₹3,499.35 crore in FY26; net debt to EBITDA at 1.14x and net debt to equity at 0.25x
Board approves up to ₹500 crore additional investment in wholly owned subsidiary Mankind Medicare in multiple tranches
Security cover on listed NCDs to be realigned after ₹1,250 crore debenture redemption
Executive leadership updates, including re‑appointment of a whole‑time director and CIO resignation
Income‑tax proceedings ongoing; management does not expect material adverse impact